Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 2/20 | 0.74 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | NOS1 | P29475 | 2/20 | 0.57 |
| ▸ | NOS3 | P29474 | 1/20 | 0.57 |
| ▸ | NOS2 | P35228 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.56 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.55 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CHKA | P35790 | 1/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzylamine SCHEMBL27789840 | 0.91 | NCF1 (0.78) | NCF1HRH3SMN1; SMN2NOS1ALDH1A1 | |
| SCHEMBL26094765 | 0.90 | NCF1 (0.62) | NCF1HRH3SMN1; SMN2NOS1NOS3 | |
| SCHEMBL15467001 | 0.89 | HRH3 (0.87) | NCF1HRH3SMN1; SMN2NOS1NOS3 | |
| Hydrochloric Acid SCHEMBL26095071 | 0.88 | NCF1 (0.60) | NCF1HRH3SMN1; SMN2NOS1NOS3 | |
| SCHEMBL110388 | 0.85 | NCF1 (1.00) | NCF1HRH3SMN1; SMN2NOS1ALDH1A1 | |
| SCHEMBL29350303 | 0.85 | NCF1 (1.00) | NCF1HRH3SMN1; SMN2NOS1ALDH1A1 | |
| SCHEMBL24564964 | 0.85 | PRMT6 (0.69) | NCF1HRH3ALDH1A1LMNAPRMT6 | |
| SCHEMBL27630736 | 0.85 | HRH3 (0.67) | NCF1HRH3SMN1; SMN2NOS1NOS3 | |
| SCHEMBL3719689 | 0.84 | NCF1 (0.73) | NCF1HRH3SMN1; SMN2NOS1ALDH1A1 | |
| SCHEMBL60797 | 0.84 | HRH3 (0.71) | NCF1HRH3SMN1; SMN2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113956489-A | Modified epoxy emulsifier, preparation method thereof and self-modified epoxy emulsion | 重庆国际复合材料股份有限公司 | 2022-01-21 | — | — | CN | claimed |
| US-RE50878-E1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-05-05 | — | — | US | disclosed |
| US-12227482-B2 | Compounds and compositions for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-18 | — | — | US | disclosed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| CN-114075180-B | Immunomodulatory compounds and anti-tumor applications thereof | 上海科技大学 | 2024-04-05 | — | — | CN | disclosed |
| CN-112601751-B | Fused thiophene compounds | 拜欧斯瑞克斯公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4339192-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | The Regents of the University of California (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-3478284-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230303539-A1 | IMMUNOREGULATORY COMPOUND AND ANTITUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2023-09-28 | — | — | US | disclosed |
| CN-115057831-B | Thiadiazole compound and application thereof in preparation of KKBC 1 protein inhibitor | 中国医科大学附属盛京医院 | 2023-08-04 | — | — | CN | disclosed |
| WO-2007028083-A2 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007028083-A2 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20060293379-A1 | Quaternary salt CCR2 antagonists | KENVUE BRANDS LLC | 2006-12-28 | — | — | US | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006031929-A2 | THIAZOLOPYRIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-23 | — | — | WO | disclosed |
| US-20060058341-A1 | Thiazolopyridine kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-16 | — | — | US | disclosed |
| WO-2006012135-A1 | QUATERNARY SALT CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA, N. V. (BE) | 2006-02-02 | — | — | WO | disclosed |
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2005-05-19 | — | — | US | disclosed |
| US-20050038014-A1 | 5'-carbamoyl-1,1' biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-02-17 | — | — | US | disclosed |
| US-6288061-B1 | INTERLEUKIN INHIBITORS; ASTHMA, BRONCHODILATOR AGENTS, ANTIALLERGENS | WELFIDE CORPORATION (JP) | 2001-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303539-A1 | IMMUNOREGULATORY COMPOUND AND ANTITUMOR APPLICATION THEREOF | TNF, NFATC1, IL2 | NCF1 214/4885HRH3 3768/4885SMN1; SMN2 3725/4885 |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | NCF1 1648/4885HRH3 168/4885SMN1; SMN2 3900/4885 |
| US-20050038014-A1 | 5'-carbamoyl-1,1' biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors | MAPK1, MAP4K2, MAP3K1 | NCF1 1197/4885HRH3 2019/4885SMN1; SMN2 2814/4885 |
| US-20060058341-A1 | Thiazolopyridine kinase inhibitors | PRKACA, PRKCE, MAP3K9 | NCF1 1643/4885HRH3 2613/4885SMN1; SMN2 4831/4885 |
| US-12227482-B2 | Compounds and compositions for the treatment of cancer | TP53, HCCS, CFTR | NCF1 1147/4885HRH3 2857/4885SMN1; SMN2 3421/4885 |
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | ARRB1, OPRL1, CNR1 | NCF1 1315/4885HRH3 271/4885SMN1; SMN2 4257/4885 |
| US-20060293379-A1 | Quaternary salt CCR2 antagonists | CCR2, CCR1, CXCR2 | NCF1 420/4885HRH3 790/4885SMN1; SMN2 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.